Taking Immunosuppressant Medicines and Starting Immunotherapy — What Actually Has to Change

Usually not completely. Most immune-suppressing medicines are reviewed and brought down to the lowest dose that still controls your condition, rather than stopped. Some are continued unchanged. What happens depends on why you take it and how much you take, and the decision is made by your oncologist together with the specialist who prescribes it.

The reason there is a question at all is mechanical rather than mysterious. Immune-suppressing medicines are given to hold the immune system back. Checkpoint inhibitor immunotherapy works by taking a brake off that same immune system so it can act against cancer. The two aims point in opposite directions, in the same body, at the same time — so the sensible response is to find the level of suppression that keeps your condition safe while leaving immunotherapy something to work with.

That is a balancing exercise, not a barrier. It is also why a one-line refusal is unsatisfying. “You are on immunosuppressants” describes your prescription; it does not describe your dose, your stability, or whether a lower dose would hold. Those are the things an assessment is supposed to establish.

This page is general patient education and cannot tell you whether immunotherapy is suitable for you. That judgement needs your cancer details, your current medicines with doses, and how stable your underlying condition is, in front of a medical oncologist working with your prescribing specialist.

In most cases, no. The medicine is reviewed rather than stopped, and the target is the lowest dose that keeps your condition controlled. Some people taper gradually before treatment. Some continue exactly as they are. Stopping outright is uncommon, because the consequences of stopping are often worse than the dose itself.

Those consequences are the part that gets skipped. An autoimmune condition that flares because treatment was withdrawn can delay cancer treatment for weeks and may need high-dose steroids to settle — which leaves you more immune-suppressed than you were before, not less. In a transplant recipient, reducing anti-rejection medicine can put the graft itself at risk. Neither outcome helps the cancer plan.

There is also a difference between suppressing an immune system and replacing a hormone. Steroid tablets given because your body can no longer make enough of its own are doing a replacement job, and are generally regarded differently from the same tablets given at higher doses to damp an immune reaction down. If you have been on long-term steroids, ask your team which of the two situations applies to you, because the answer changes the conversation completely.

Where a reduction is agreed, it is staged and supervised. Nobody should be asked to come down quickly so that a treatment date can be kept. If the dose genuinely cannot come down — and for some conditions it cannot — that is a legitimate finding, and immunotherapy is then weighed against it honestly rather than pushed through or refused without explanation. Other treatment options are considered in the same discussion. Patients living with psoriasis or with lupus or scleroderma often find the medicine question is the whole of the eligibility question.

Low, stable maintenance doses are commonly regarded as compatible with immunotherapy. Higher doses attract more caution. Retrospective analyses have suggested that patients on substantial immune suppression when treatment starts tend to do less well — although those patients often had other reasons to do less well, such as more active disease, so the association is not a simple cause. The registration trials largely excluded people on higher baseline immunosuppression, which is exactly why the evidence here is thinner than it should be and comes mostly from registries and reported series.

A low daily steroid equivalent has commonly been used as the cut-off in trial eligibility criteria, and that reference point is echoed in guidance from bodies such as ASCO, ESMO and NCCN. Treat it as a reference point and not as a rule about you. Being marginally above it is not a refusal, and being below it is not a clearance. The category of medicine, how long you have taken it and how stable you are all weigh alongside the number.

General patterns only, not instructions for your case, and not a substitute for your own teams’ assessment in either direction. Medicine categories are described here rather than named, because which specific medicine you take, at what dose, is a prescribing decision for your specialist and not something to settle from a web page.

At CION this is discussed in a multidisciplinary tumour board and, where the prescribing specialist sits outside CION, directly with their clinic. If you have already been turned down with no reasoning attached, a second opinion from a medical oncologist is reasonable — not to find someone who will say yes, but to find out whether the dose question was ever actually asked.

• Do not stop steroid tablets suddenly — after more than a few weeks they must be reduced gradually. Stopping abruptly can cause a serious fall in your body’s own steroid production.
• Do not skip a biologic injection to “clear it” first — these medicines stay active for a long time, and an unplanned gap can restart the condition without changing the timing question.
• Do not reduce anti-rejection medicine — only the transplant unit that follows your graft can change that, and only as part of an agreed plan.
• Do not leave anything off the list — over-the-counter, herbal and traditional preparations, and prescriptions from another clinic, all belong on it. Disclosure is the point, not judgement.
• Do not let the two clinics communicate only through you — ask for a letter or a direct call between them, and ask for a copy.

• If you have already been turned down and the reason was never explained, Second Opinion When You Have Been Refused Immunotherapy sets out exactly what to ask for.
• If the medicine is for a skin condition, Immunotherapy With Psoriasis covers how flares are anticipated and managed alongside treatment.
• If it is for a connective-tissue disease, Immunotherapy With Lupus or Scleroderma explains why these conditions are assessed more cautiously.
• For how immunotherapy is delivered, monitored and followed up as day care, see Immunotherapy at CION Cancer Clinics.

General patient-education information only. Nothing here states or implies that immunotherapy is suitable or unsuitable for you, and no medicine, dose or taper should be changed on the basis of this page — those decisions belong to your treating medical oncologist and the specialist who prescribes your immune-suppressing medicine, together. Immunotherapy is administered as day care at CION centres; CION does not provide CAR-T or other cell therapies. Response-assessment PET-CT is coordinated at partner imaging centres.

One Plan, Agreed by Both Your Doctors

A medical oncologist can set out what your current immune suppression means for immunotherapy, and speak directly to the specialist who prescribes it.

This page is general patient-education information, not a substitute for the written plan your own medical oncologist and prescribing specialist agree for your specific case.